Unilam Co., LTD's UV sunlamps violate quality-system and radiation-safety testing rules, FDA says.
What happened
FDA inspected Unilam's facility in Ulju-gun, Ulsan, South Korea, from 05/18/2026 through 05/22/2026 and found its SUV 600-800/KT/GYU UV Sunlamp adulterated under the Quality System regulation. FDA also determined the sunlamps fail federal electronic product radiation control requirements, citing inadequate risk management, design validation, supplier controls, calibration, sampling, and certification-testing documentation.
What FDA found
Unilam lacked an adequate design risk-management process; its design risk analysis covered only four items and did not address foreseeable risks such as chemical exposure if a lamp breaks.
ISO 13485:2016 Clause 7.1; 21 CFR Part 820Design validation and change control were inadequately documented, including no UVC emission results over the full 800-hour expected lifetime and no clear design-control procedure.
ISO 13485:2016 Clause 7.3.1; 21 CFR Part 820Supplier evaluation and selection criteria were inadequate, and a quartz-tube supplier evaluation was contradictory, marked "Not Registered" at the minimum passing score.
ISO 13485:2016 Clause 7.4.1Unilam lacked written agreements requiring quartz-tube, mercury, and krypton suppliers to notify it of changes before implementation.
ISO 13485:2016 Clause 7.4.2Calibration and monitoring procedures for the integrating sphere did not cover the UVC/UVB ranges used and did not adequately requalify the equipment after a 2021 fire.
ISO 13485:2016 Clause 7.6Certification testing and sampling lacked documented statistical basis, measurement details, aging evidence, and worst-case justification needed to show compliance with the sunlamp performance standard.
21 CFR 1040.20(f); 21 CFR 1010.2; ISO 13485:2016 Clause 8.2.6
What FDA wants
FDA asks Unilam to respond in writing within 15 business days with steps to correct the violations, prevent recurrence, and provide the requested radiation-testing documentation, including measurement details, aging evidence, worst-case justification, and sampling-plan validation. If actions will take longer, the company must include a timetable.
Who should pay attention
- US importers and distributors of UV sunlamps
- sunlamp bed manufacturers that rely on these lamps
- medical-device quality teams handling supplier and design controls
This is a summary. Read the original letter on fda.gov.